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BACKGROUND: Brain metastases (BM) constitute the most common intracranial tumours and are associated with considerable
morbidity and mortality. Population-based studies of the epidemiology and time trends of BM are scarce.
METHODS: A population-based cohort of patients admitted to hospital with BM in Sweden between 1987 and 2006 (n¼15517) was
identified and linked to nationwide registers of cancer incidence and death. Primary cancer types were assessed and time to
hospitalisation and death was computed.
RESULTS: The annual age-adjusted incidence rate of hospitalisation for BM doubled from 7 to 14 patients per 100000 between 1987
and 2006. The most common primary tumours among women were lung (33%), breast (33%) and colorectal cancer (7%), and
among men lung cancer (44%), malignant melanoma (12%) and colorectal cancer (9%). The increase was most evident for BM
patients with lung cancer (both sexes) and breast cancer (women). Survival was short, with a median of 2.7 months. It varied little by
cancer type and did not improve over calendar time.
CONCLUSION: The number of patients admitted with BM has increased rapidly in Sweden. In spite of recent improvements in the
prognosis of common primary cancer types, any parallel improvement among patients with advanced cancer and BM is not indicated.
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Brain metastases (BM) constitute the most common type of
intracranial neoplasms (Gavrilovic and Posner, 2005), and in the
US alone, more than 100000 persons are diagnosed annually
(Nathoo et al, 2004). The incidence of BM is believed to be
increasing, not only because of the advances in the treatment of
patients diagnosed with primary malignancies and decreased
mortality but also because of the technical advances in neuro-
imaging (Barnholtz-Sloan et al, 2004; Gavrilovic and Posner, 2005).
Although the evidence of such a trend is limited (Schouten et al,
2002), a future increase may be expected because of an increasingly
large pool of prevalent cancer patients at risk of developing
metastatic disease.
The cancer types most frequently recurring with BM are lung,
breast, kidney and colorectal carcinomas, and malignant melano-
mas (Schouten et al, 2002; Barnholtz-Sloan et al, 2004). Patients
with lung cancer appear to have the highest propensity for BM
(Hochstenbag et al, 2000; Schouten et al, 2002). However, studies
of the incidence and/or survival of patients with BM are often
confined to one single primary cancer type. They constitute single-
centre experiences or are based on autopsied patients (Johnson
and Young, 1996; Nussbaum et al, 1996; Schouten et al, 2002),
making incidence estimates uncertain and comparisons between
tumour types difficult. Population-based investigations are
either old (Guomundsson, 1970; Walker et al, 1985) or confined
to major cancer types (Barnholtz-Sloan et al, 2004). Consequently,
there is a need for better understanding of the contemporary
epidemiology of patients with BM and recent time trends in
population-based settings.
We used Swedish national population-based high-quality
health-care registers to investigate patient characteristics, types
of primary malignancies, survival and time trends in a cohort of
15517 patients hospitalised with BM during a 20-year period.
MATERIALS AND METHODS
Patients
We identified a cohort of individuals with BM in the Swedish
National Patient Registry (National Patient Registry, 2009). This
register holds individualised information on inpatient care county-
wise since 1964 and nation-wide since 1987. For every hospital
discharge, dates of admission and discharge, and up to eight
discharge diagnoses are recorded according to the ICD classifica-
tion, and the total number of register dropouts for somatic care
has been estimated to be o2%. As there is practically no private
inpatient care in Sweden, the registration of hospital admissions is
population-based and independent of private health insurances or
socioeconomic status. The cohort consisted of all patients
hospitalised with BM as a primary or secondary diagnosis in
Sweden from 1 January 1987 to 31 December 2006. The ICD codes
used were C793 (ICD10) and 198D (ICD9), representing metastases
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yoriginating in the brain or meninges. The date of the first hospital
admission was used as the index date for each patient.
To obtain information on the primary cancer site, the patients in
the cohort were matched to the National Cancer Registry (NCR)
(National Cancer Registry, 2009) by the national registration
numbers assigned to all Swedish citizens. The NCR was established
in 1958 and is estimated to be 495% complete overall, with some
variation by primary cancer type (Barlow et al, 2009). We initially
identified 16175 patients admitted with BM in the NPR. However,
following matching with the NCR, we excluded 445 patients who
were concomitantly registered with a primary brain tumour. We
also excluded 213 individuals with a record of a haematopoietic
malignancy, as their admission for BM may represent malignant
central nervous system (CNS) involvement that is clinically and
biologically distinct from metastases of solid cancers. Hence,
15517 individuals with BM were included in the final study cohort.
Of these, 12307 patients (79%) were recorded in the NCR with one
primary solid cancer diagnosis either preceding the index date of
admission to hospital for BM (no maximum time limit was
applied), or during the first 180 days following this date. An
additional 1424 individuals (9%) had records of more than one
primary cancer type. For these patients, we chose the cancer type
diagnosed closest in time to the index date as the most probable
primary cancer. For 1786 individuals (12%), there was no record of
a primary solid cancer in the NCR during the stipulated time
interval around BM admission. Among these, 13 individuals were
however recorded in the NCR with a first solid cancer more than 1
year after first hospitalisation for BM, 184 with benign tumours
only, 492 with BM only, and 1097 were not found. In spite of the
lack of NCR records of a primary malignancy for these 1786
individuals, almost half had a concomitant admission diagnosis of
a primary cancer listed in the NPR. However, as the specificity of
the primary cancer type in the NPR may be less valid, these were
left aside.
Finally, the cohort of BM patients was matched through their
national registration numbers to the Cause-of-Death Registry. This
national register holds computerised information on dates and
causes of death for Swedish residents since 1952 and the
completeness exceeds 99% (National Cause-of-Death Registry,
2009). All individuals were followed from the index date of first
admission with BM to the date of death, or 31 December 2006,
whichever came first. The national registers used are maintained
by the Centre of Epidemiology at the Swedish National Board of
Health and Welfare. The study was approved by the Stockholm
Regional Research Ethics Board (Dnr 2007/1112-31/2).
Statistical analyses
The incidence rate of patients admitted with BM per 100000
Swedish residents and year during 1987 to 2006 was standardized
to the age distribution of the population in 1995. The time from the
primary solid cancer diagnosis to the index date of first admission,
as well as the time from the index date to death, was computed as
the median time in months with interquartile range, and was
stratified by sex, age, type of primary cancer and calendar period.
The assessment of time from the primary solid cancer diagnosis to
the index date was restricted to the group of patients with only
one recorded primary cancer. In this group, we also used a
multivariable Cox proportional hazards model to compute hazard
ratios (HRs) and 95% confidence intervals (CIs) as a complemen-
tary analysis for comparison of the time between the primary
cancer diagnosis and BM admission by cancer type and patient
characteristics. The multivariate model included age, sex and
calendar period. Survival was analysed as the median survival time
in months, as 1-year survival proportions using the Kaplan–Meier
method, and in a multivariable Cox proportional hazards model to
estimate the relative risk (HR and 95% CI) of death according to
primary cancer types and other covariates.
RESULTS
The incidence of patients hospitalised with BM in Sweden doubled
from 7 per 100000 persons and year in 1987 to 14 per 100000
persons and year in 2006 (Figure 1). The cohort included more
women than men, and about one-third (33%) of the patients were
younger than 60 years at first hospitalisation (Table 1). The
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Figure 1 (A) Brain metastases admissions in Sweden between 1987 and
2006: age-standardized* rate of patients admitted with BM per 100000
persons and year. (B) Brain metastases admissions in Sweden between
1987 and 2006: age-standardized* rate of male patients admitted with BM
per 100000 persons and year. (C) Brain metastases admissions in Sweden
between 1987 and 2006: age-standardized* rate of female patients
admitted with BM per 100000 persons and year. *The Swedish population
in the year 1995 was used as the standard.
wIncluded mainly cancer in the
upper gastrointestinal tract, bladder and ear–nose–throat area.
Brain metastases in Sweden
KE Smedby et al
1920
British Journal of Cancer (2009) 101(11), 1919–1924 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ymedian age at first admission was 67 years among men and 64
years among women. Half of the patients (50%) were admitted
with BM as the primary or main diagnosis, and the other half were
admitted with BM secondary to other cancer diagnoses (43%) or to
non-cancer disorders/complications (7%).
Among individuals with one primary solid cancer, the most
common cancer types in men were lung cancer (44%), malignant
melanoma (12%), colorectal cancer (9%) and prostate cancer (9%).
In women, lung cancer and breast cancer were equally common
(approximately 33%), followed by colorectal cancer (7%) and
malignant melanomas (6%). In patients with a history of multiple
cancer types, lung cancer was the most common type in both men
and women (39 and 41%, respectively, Table 1).
The median time between diagnosis of the primary cancer and
first admission with BM varied from 2.6 months in patients with
lung cancer to more than 3 years in patients with malignant
melanoma or breast cancer, and was almost twice as long among
women compared with men (Table 2). Excluding gender-specific
malignancies, time to admission was still longer in women
compared with men with lung cancer or malignant melanoma,
whereas there was no difference by gender among patients with
colorectal, kidney or other cancer types when taking age and
calendar period differences into account (data not shown). Overall,
the time to first admission increased with age, more so in women
than in men (men X80 years of age HR 0.81, women X80 years of
age HR 0.69, compared with individuals younger than 50 years,
Table 2). The time to hospitalisation also increased over successive
calendar periods among men (HR 0.85 for the period 2002 to 2006
compared with 1987 to 1991, Table 2), but remained unchanged
among women.
Median survival from admission with BM was short, 2.7 months,
and did not vary by the number of recorded primary cancers
(Table 3). By cancer type, the survival time ranged from 2.5
months among patients with lung cancer to 4.7 months among
those with kidney cancer. Similarly, the proportion of patients
still alive 1 year after first admission was 13% overall, ranging
from 10% in lung cancer patients to 21% in kidney cancer patients.
For the vast majority of patients who died during follow-up, the
primary cancer type was registered as the main cause of
death. High age at admission for BM was a strong predictor of
death among both men and women. There was no improvement in
the median survival time or the 1-year survival proportion
over successive calendar periods. On the contrary, in the adjusted
analysis, there was a small increase in risk of death between
2002 and 2006 compared with between 1987 and 1991 in both
sexes.
DISCUSSION
In summary, we observed that the age-adjusted incidence of
patients admitted to hospital with BM doubled during the period
Table 1 Brain metastases (BM) admissions in Sweden between 1987 and 2006: characteristics of men and women admitted with BM and type of primary
cancer
Men Women
Primary cancer
in the Cancer Registry
Primary cancer in
the Cancer Registry
Characteristic Total
One
cancer
More than
one cancer
No primary
cancer
a Total
One
cancer
More than
one cancer
No primary
cancer
a
Total 7276 5672 687 917 8241 6635 737 869
Row % by sex 78.0 9.4 12.6 80.5 8.9 10.5
Age at first admission (years)
Median 67 66 72 70 64 62 68 70
Q-range 59–74 58–73 66–78 61–77 55–72 54–71 60–75 58–79
Number Row % Number Row %
o50 576 89.1 1.9 9.0 1182 90.9 2.3 6.9
50–59 1339 85.1 4.3 10.6 2000 85.7 6.6 7.8
60–69 2318 81.1 8.2 10.7 2325 81.0 10.5 8.5
70–79 2254 72.2 13.3 14.5 1961 75.2 12.3 12.5
80+ 789 65.0 16.1 18.9 773 63.4 12.0 24.6
Calendar period
1987–1991 901 82.8 6.4 10.8 802 80.0 7.5 12.5
1992–1996 1417 81.1 7.8 11.2 1491 82.1 8.5 9.5
1997–2001 2196 76.1 9.2 14.7 2547 79.1 9.1 11.8
2002–2006 2762 76.2 11.5 12.3 3401 81.0 9.4 9.6
Column % Column %
Type of primary cancer
b
Lung cancer 44.1 39.4 33.5 41.0
Breast cancer — — 32.6 15.1
Colorectal cancer 9.0 10.5 7.4 7.2
Malignant melanoma 12.3 6.4 5.8 5.8
Female genital cancer — — 5.6 8.8
Kidney cancer 7.8 7.3 4.7 5.4
Prostate cancer 8.6 13.1 — —
Other solid cancers
c 18.2 23.3 10.5 16.7
aPatients with no solid cancer diagnosis in the Swedish Cancer Register.
bFor patients with more than one primary solid cancer reported to the Swedish Cancer Register, the
diagnosis closest in time to the date of admission with BM was chosen-.
cIncluded mainly cancer in the upper gastrointestinal tract, bladder and ear–nose–throat area.
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increase were mainly lung cancer in both sexes and breast cancer
in women. The median time from primary cancer diagnosis to BM
admission varied greatly, from 3 months in patients with lung
cancer to 42 months in breast cancer patients. However, overall,
the time to admission remained largely unchanged over the period
of study. In contrast, the survival time from first admission was
short, with a median of 3 months, varied little by cancer type, and
decreased slightly over calendar time.
In a study from the Netherlands, including 1700 lung or breast
cancer patients with BM diagnosed from 1986 to 1998 (Schouten
et al, 2002), no similar increase in the incidence of BM was noted.
The discrepancy between the studies could be attributed not only
to different definitions of the population at risk when computing
incidence estimates, but also to a shorter time period of
observation in the Dutch study. Indeed, we noted an increase in
the incidence of BM patients with lung or breast cancer from the
middle of the 1990s and onwards, whereas during the earliest
period, 1987 to 1990, the incidence decreased.
The annual age-adjusted incidence rate of all primary malig-
nancies in Sweden increased from 490 to 530 per 100000
individuals during the period 1987 to 2006 (Cancer Incidence in
Sweden, 2007). For many cancer types, there has been a parallel
improvement in prognosis (Lin and Winer, 2007; Vora and
Reckamp, 2008), likely in part because of the earlier detection of
indolent tumours (Cancer Incidence in Sweden, 2007), but also
because of the introduction of more effective treatment. The
prevalence of cancer (ever diagnosed) increased from 3236 per
100000 in 1997 to 4130 in 2006 in Sweden, in an increasingly older
population (Cancer Incidence in Sweden, 1999, 2007). This has
plausibly resulted in a higher prevalence of patients at risk of
developing metastatic disease.
The incidence rates of lung cancer in many Western countries,
including Sweden, have stabilized and even decreased in recent
years among men, whereas an increasing trend is still evident
among women (Cancer Incidence in Sweden, 2007; Toh, 2009).
Brain metastases are a common event in lung cancer, observed in
10–20% of patients screened at diagnosis of a non-small-cell lung
cancer (Gavrilovic and Posner, 2005), and even more frequently in
small-cell lung cancer patients (Castrucci and Knisely, 2008). With
time from lung cancer diagnosis, the proportion of patients
developing BM increases rapidly (Mujoomdar et al, 2007; Slotman
et al, 2007). A reported improvement in the short-term survival
(Slotman et al, 2007; Vora and Reckamp, 2008) may therefore,
together with a presumed inefficiency of systemic therapy beyond
the blood–brain barrier (Slotman et al, 2007), constitute
important prerequisites for the increased numbers of lung cancer
patients admitted with BM of both sexes in our study. As routine
brain scans are seldom performed in asymptomatic patients in
Sweden, and prophylactic cranial irradiation is still uncommon,
the impact of these measures is limited.
Breast cancer incidence has increased slowly over the past 20
years in Swedish women (Cancer Incidence in Sweden, 2007),
partly because of earlier detection through mammography screen-
ing, but also because of the lower parity and increasing age of
mothers at first birth as well as the widespread use of hormonal
Table 2 Brain metastases (BM) admissions in Sweden between 1987 and 2006: time from primary solid cancer diagnosis to first admission with BM
a
Adjusted time
b
to admission with BM
Time to admission
with BM (months) Men Women
Characteristic n Median (Q-range) HR (95% CI)
b HR (95% CI)
b
Type of primary cancer 12307 12.2 (1.2–37.0)
Lung cancer 4724 2.6 (0.0–10.2) 3.15 (2.86–3.48) 2.92 (2.64–3.23)
Breast cancer 2163 41.7 (20.4–78.0) — 0.52 (0.47–0.58)
Colorectal cancer 1001 25.2 (10.5–45.5) 1.00 (reference) 1.00 (reference)
Malignant melanoma 1087 38.6 (20.0–69.9) 0.74 (0.66–0.83) 0.48 (0.42–0.55)
Female genital cancer 370 25.8 (11.5–56.6) — 0.63 (0.55–0.73)
Kidney cancer 749 17.0 (3.1–47.8) 1.02 (0.90–1.16) 0.90 (0.78–1.04)
Prostate cancer 485 27.2 (10.2–61.4) 0.90 (0.80–1.02) —
Other solid cancers
c 1728 5.2 (0.0–21.1) 1.50 (1.35–1.67) 1.44 (1.28–1.62)
Sex
Men
Women 5672 8.8 (0.5–28.3)
6635 16.3 (2.6–45.5)
Age
d (years)
o50 1587 18.2 (4.7–43.2) 1.00 (reference) 1.00 (reference)
50–59 2852 11.5 (1.3–34.3) 1.02 (0.92–1.14) 0.83 (0.77–0.89)
60–69 3762 10.4 (0.9–31.5) 0.99 (0.89–1.09) 0.74 (0.68–0.80)
70–79 3103 11.3 (0.9–38.5) 0.92 (0.83–1.02) 0.67 (0.62–0.73)
80+ 1003 17.5 (1.5–51.7) 0.81 (0.71–0.92) 0.69 (0.62–0.77)
Calendar period
1987–1991 1388 11.8 (0.2–35.0) 1.00 (reference) 1.00 (reference)
1992–1996 2373 13.8 (1.1–40.2) 0.91 (0.83–1.00) 1.03 (0.94–1.14)
1997–2001 3687 11.5 (1.2–35.3) 0.91 (0.84–1.00) 1.04 (0.95–1.13)
2002–2006 4859 12.1 (1.7–37.1) 0.85 (0.79–0.93) 1.02 (0.93–1.11)
aThe analyses were restricted to BM patients with only one primary solid cancer recorded (12307 out of 15517, 79%).
bTime from the primary solid cancer diagnosis to
admission with BM computed as hazard ratio (HR) and 95% confidence interval (CI) in a multivariate Cox regression model including adjustment for age, sex and calendar period,
except in analyses of main effects of each covariate.
cIncluded mainly cancer in the upper gastrointestinal tract, bladder and ear–nose–throat area.
dAge at first admission to
hospital with BM.
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yreplacement therapy among Swedish women (Cancer Incidence in
Sweden, 2007). These changes, as well as a general improvement in
the prognosis of breast cancer (Cancer Incidence in Sweden, 1999;
2007; Lin and Winer, 2007), provide a basis for the substantial
increase observed in breast cancer patients hospitalised with BM.
The reported incidence of BM among women diagnosed with
breast cancer ranges from 5 to 20% (Schouten et al, 2002;
Barnholtz-Sloan et al, 2004). Characteristics repeatedly associated
with an increased BM risk include young age, oestrogen receptor-
negative tumours and advanced stage at primary diagnosis
(Palmieri et al, 2006; Lin and Winer, 2007), whereas the potential
predictive value of HER-2 (expressed in 20–30% of breast
tumours) is more uncertain (Palmieri et al, 2006). The introduc-
tion of adjuvant anti-HER-2 antibody treatment, trastuzumab, with
low presumed efficiency in the CNS, may have altered the natural
history of patients with HER-2-positive breast cancer and
unmasked CNS as a potential sanctuary site (Lin and Winer,
2007). This ‘HER-2 paradigm’ may also be relevant for other breast
cancer patients in whom successful control of the disease outside
of the CNS is achieved with adjuvant or palliative chemo- and
radiotherapy (Lin and Winer, 2007).
In spite of a steady increase in incidence of malignant
melanomas in Sweden during the investigated period (Cancer
Incidence in Sweden, 2007), we did not observe any corresponding
increase in melanoma patients admitted with BM. As the increase
in primary melanoma incidence may be largely confined to early-
stage tumours with very low, if any, metastatic potential (Rees,
2008), the pool of prevalent patients truly at risk of metastatic
disease may have increased much less. Alternatively, we may have
failed to detect a true modest increase as our study was limited to
hospitalised patients. Similarly, the lack of clear time trends for
BM patients with colorectal, prostate, kidney or female genital
cancer should be interpreted with caution. Prostate cancer was the
fourth most common primary malignancy among men admitted
with BM in our study. However, we cannot exclude some degree of
misclassification of skull or skull base metastases as BM because of
the similarity of symptoms. Patients with BM attributed to prostate
cancer have not been included in previous studies of BM patients,
which limits the possibilities of comparison (Schouten et al, 2002;
Barnholtz-Sloan et al, 2004).
Survival following first admission with BM was on average
median shorter than 3 months, and the 1-year survival proportion
was only 13%. The highest 1-year survival proportions, around
20%, were observed for patients with kidney, breast or prostate
cancer, which is in line with previous reports for breast cancer
(Palmieri et al, 2006; Altundag et al, 2007), whereas studies for
prostate cancer are scarce. In a US study of patients with BM from
renal cell carcinoma (Shuch et al, 2008), 1-year survival was,
however, 48%. The discrepancy may be explained by the use of
time from hospital admission to death in our study rather than
from diagnosis, but also perhaps by differences in CNS-screening
routines between the United States and Sweden.
Table 3 Brain metastases (BM) admissions in Sweden between 1987 and 2006: survival from first admission with BM
Proportion
deceased Survival (months)
One-year survival
proportion
Relative risk
a of death
following admission with BM
Number %
Median
(Q-range) % (95% CI)
Men HR
(95% CI)
a
Women HR
(95% CI)
a
Total 15517 97.5 2.7 (1.2–6.5) 13.0 (12.5–13.6)
One primary cancer 12307 97.8 2.7 (1.2–6.7) 13.3 (12.7–13.9)
Lung cancer 4724 98.7 2.5 (1.2–5.9) 10.4 (9.5–11.3) 1.07 (0.97–1.18) 1.03 (0.93–1.14)
Breast cancer 2163 96.9 3.2 (1.2–9.1) 19.0 (17.4–20.7) — 0.92 (0.83–1.01)
Colorectal cancer 1001 99.0 2.6 (1.4–5.1) 6.7 (5.3–8.4) 1.00 (reference) 1.00 (reference)
Malignant melanoma 1087 97.9 2.7 (1.1–5.9) 9.8 (8.2–11.7) 1.08 (0.96–1.22) 1.03 (0.90–1.17)
Female genital cancer 370 97.0 2.9 (1.3–7.8) 18.4 (14.6–22.4) — 0.87 (0.76–1.00)
Kidney cancer 749 96.4 4.7 (2–10.3) 21.1 (18.3–24.1) 0.69 (0.60–0.78) 0.67 (0.58–0.78)
Prostate cancer 485 97.7 2.9 (1.2–8.0) 19.4 (16.0–23.0) 0.72 (0.63–0.81) —
Other solid cancers
b 1728 96.4 2.5 (1.1–6.3) 13.7 (12.1–15.3) 0.98 (0.88–1.09) 0.94 (0.83–1.05)
More than one cancer 1424 98.2 2.4 (1.1–5.6) 9.7 (8.2–11.3) 1.01 (0.90–1.13) 0.91 (0.81–1.02)
No primary cancer
c 1786 94.9 2.6 (1.3–6.3) 14.2 (12.6–15.9) 0.85 (0.76–0.95) 0.79 (0.71–0.89)
Sex
Men 7276 97.8 2.5 (1.2–6.0) 11.4 (10.7–12.1)
Women 8241 97.2 2.9 (1.3–7.2) 14.4 (13.7–15.3)
Age
d
o50 1758 93.8 4.5 (1.6–11.4) 23.6 (21.6–2.6) 1.00 (reference) 1.00 (reference)
50–59 3339 97.0 3.5 (1.4–8.8) 18.0 (16.7–19.3) 1.24 (1.12–1.37) 1.18 (1.09–1.27)
60–69 4643 97.5 2.9 (1.3–6.8) 12.9 (11.9–13.9) 1.44 (1.31–1.58) 1.36 (1.26–1.46)
70–79 4215 98.9 2.2 (1.1–4.6) 8.1 (7.3–8.9) 1.89 (1.71–2.08) 1.70 (1.57–1.83)
80+ 1562 98.6 1.8 (0.9–3.2) 4.6 (3.6–5.7) 2.42 (2.16–2.72) 2.17 (1.97–2.39)
Calendar period
1987–1991 1703 98.2 3.6 (1.6–8.3) 17.5 (15.7–19.3) 1.00 (reference) 1.00 (reference)
1992–1996 2908 98.9 3.0 (1.3–7.6) 14.8 (13.5–15.1) 1.05 (0.97–1.14) 1.11 (1.02–1.21)
1997–2001 4743 98.3 2.5 (1.2–6.1) 11.8 (10.9–12.7) 1.17 (1.08–1.27) 1.19 (1.10–1.29)
2002–2006 6163 96.0 2.5 (1.1–5.9) 12.0 (11.2–12.8) 1.18 (1.09–1.27) 1.18 (1.09–1.28)
aRelative risk of death following admission with BM computed as hazard ratio (HR) and 95% confidence interval (CI) in a multivariable Cox regression model compared with a
reference.
bIncluded mainly cancer in the upper gastrointestinal tract, bladder and ear–nose–throat area.
cPatients with BM in the Patient register but with no solid cancer in the
Swedish Cancer Register.
dAge at first admission with BM.
Brain metastases in Sweden
KE Smedby et al
1923
British Journal of Cancer (2009) 101(11), 1919–1924 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yOur study covered two decades and was based on comprehen-
sive reporting of all hospital admissions and primary malignan-
cies, and on a virtually complete follow-up. To our knowledge, no
national studies of patients with BM encompassing all primary
cancer types have been published previously. Our data give
important information about an expanding group of patients with
a significant need for supportive care and thus generating high
health-care costs (Taillibert and Delattre, 2005). The study was,
however, limited to patients hospitalised with BM. Although it is
feasible to believe that the majority of patients diagnosed with BM
are hospitalised at some point during the disease course, our
cohort most likely represents an underestimation of the number of
BM patients in the population. Also, temporal changes in the
society and in health-care routines need to be taken into account
when interpreting the observed time trend. The increasing use of
advanced neuroimaging techniques may have inflated the number
of identified BM patients. However, more conservative hospital
admission practices attributed to a general reduction of inpatient
beds could have had a counteracting effect. The introduction of
new treatment options for certain patient groups may have affected
admission rates differentially. However, any temporal changes in
admission or registration routines driven by socioeconomic or
political factors should have affected all cancer patients alike and
are less likely to explain the observed differences in time trends by
cancer type.
Another concern is that we did not have confirmatory
information about the diagnostic workup or biopsy results linking
the primary cancer to the brain lesions. For patients registered
with multiple tumours, the primary cancer diagnosed closest in
time before the date of first hospitalisation for BM was regarded as
the cancer causing BM, without validation through medical
reports. However, the distribution of cancer types among those
patients was similar to that of patients with only one primary
cancer record. An additional 12% of patients admitted with BM
were not recorded with any primary malignancy in the Swedish
Cancer Register. This group represents a mixture of patients with
unknown, or known but unreported, primary malignancies.
A degree of underreporting higher than average to the NCR has
been described for patients with lung and digestive cancer, in
validations against the Cause-of-Death Registry (Cancer Incidence
in Sweden, 2007).
To conclude, we found a doubled incidence of patients admitted
with BM during the 20-year long study period. The largest
increases were observed in patients with lung cancer and breast
cancer. Considering the recent improvements in the prognosis of
patients with lung cancer and breast cancer, the increasing
efficiency in controlling disease spread outside of the CNS, and
the short survival of advanced cancer patients with BM,
therapeutic interventions aiming at reducing the risk of BM are
essential.
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